Search research articles
Contact Us
Filters
Showing results (81-90 of 127) with videos related to
Page
of 13
Sort By:
British Journal of Haematology
|
December 10, 2015
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center
Dai Chihara, Chan Y Cheah, Jason R Westin, et al.
Blood
|
February 7, 2012
Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan
Takashi Tokunaga, Kazuyuki Shimada, Kazuhito Yamamoto, et al.
British Journal of Haematology
|
January 12, 2026
Clinical trial access after CAR T-cell therapy failure in relapsed/refractory large B-cell lymphoma
Kunhwa Kim, Rahul Shah, Amy Ayers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 29, 2020
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia
Dai Chihara, Evgeny Arons, Maryalice Stetler-Stevenson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2025
A Phase I Trial of Evorpacept, Lenalidomide and Rituximab for Patients with B-cell Non-Hodgkin Lymphoma
Paolo Strati, Lei Feng, Andrey Tyshevich, et al.
Nature Communications
|
August 7, 2025
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial
Paolo Strati, Lei Feng, Jason R Westin, et al.
Blood Advances
|
October 4, 2021
Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant
Dai Chihara, Evgeny Arons, Maryalice Stetler-Stevenson, et al.
Blood
|
February 3, 2023
Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma
Juan Pablo Alderuccio, Isildinha M Reis, Jean L Koff, et al.
Nature Genetics
|
October 21, 2025
Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphoma
Yibo Dai, Atish Kizhakeyil, Dai Chihara, et al.
British Journal of Haematology
|
July 6, 2016
Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma
Dai Chihara, Jason R Westin, Roberto N Miranda, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 127) with videos related to
Sort By:
Page
of 13
British Journal of Haematology
|
December 10, 2015
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center
Dai Chihara, Chan Y Cheah, Jason R Westin, et al.
Blood
|
February 7, 2012
Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan
Takashi Tokunaga, Kazuyuki Shimada, Kazuhito Yamamoto, et al.
British Journal of Haematology
|
January 12, 2026
Clinical trial access after CAR T-cell therapy failure in relapsed/refractory large B-cell lymphoma
Kunhwa Kim, Rahul Shah, Amy Ayers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 29, 2020
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia
Dai Chihara, Evgeny Arons, Maryalice Stetler-Stevenson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2025
A Phase I Trial of Evorpacept, Lenalidomide and Rituximab for Patients with B-cell Non-Hodgkin Lymphoma
Paolo Strati, Lei Feng, Andrey Tyshevich, et al.
Nature Communications
|
August 7, 2025
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial
Paolo Strati, Lei Feng, Jason R Westin, et al.
Blood Advances
|
October 4, 2021
Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant
Dai Chihara, Evgeny Arons, Maryalice Stetler-Stevenson, et al.
Blood
|
February 3, 2023
Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma
Juan Pablo Alderuccio, Isildinha M Reis, Jean L Koff, et al.
Nature Genetics
|
October 21, 2025
Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphoma
Yibo Dai, Atish Kizhakeyil, Dai Chihara, et al.
British Journal of Haematology
|
July 6, 2016
Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma
Dai Chihara, Jason R Westin, Roberto N Miranda, et al.
Page
of 13